Curated News
By: NewsRamp Editorial Staff
April 29, 2025
HeartBeam's 3D ECG Technology Achieves Major Milestone in Clinical Study
TLDR
- HeartBeam's 3D ECG technology achieved 93.4% diagnostic agreement, providing a competitive edge in arrhythmia assessment.
- HeartBeam's synthesized 12-lead ECG technology aims to deliver hospital-grade cardiac insights via a credit card-sized device, enhancing patient care.
- HeartBeam's innovative ECG technology revolutionizes cardiac care, empowering patients with actionable heart intelligence outside medical facilities.
- HeartBeam's cable-free 12-lead ECG captures heart signals in 3D, redefining the future of cardiac health management with portable devices.
Impact - Why it Matters
This news highlights the groundbreaking success of HeartBeam's innovative 3D ECG technology, which could revolutionize cardiac care by enabling portable, cable-free 12-lead ECGs for patients outside medical facilities. The high diagnostic agreement with standard ECGs is a significant step towards bringing advanced cardiac insights directly to patients, potentially transforming how cardiac health is managed and diagnosed.
Summary
HeartBeam (NASDAQ: BEAT) revealed that its synthesized 12-lead ECG technology successfully met clinical endpoints in the VALID-ECG pivotal study, achieving a 93.4% diagnostic agreement with standard 12-lead ECGs for arrhythmia assessment. Dr. Thomas Deering presented the results during the Heart Rhythm Society's annual conference. The company's 3D ECG technology, designed for a credit card-sized device, aims to provide hospital-grade cardiac insights to patients anywhere, with commercialization planned post-FDA clearance.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, HeartBeam's 3D ECG Technology Achieves Major Milestone in Clinical Study
